# India drug panel waives local trials for generic HIV prevention shot

2026-08-25T15:19:05+00:00 | Governance | Indian Opinion Desk

Corroboration: 2 independent outlets

India's drug regulator has moved toward allowing generic lenacapavir, a twice-yearly injectable HIV prevention drug, by recommending waiver of local Phase 3 clinical trials for Dr Reddy's Laboratories and Emcure Pharmaceuticals. The expert committee under CDSCO, at its August 11 meeting, cited an unmet medical need and recommended waiving both bioequivalence and Phase 3 trial requirements for the pre-exposure prophylaxis (PrEP) injection. Lenacapavir, developed by US firm Gilead Sciences, has shown 100% efficacy in a pivotal trial among women and 96% reduction in HIV incidence in a second trial. Generic versions are already licensed for 120 low- and middle-income countries. The recommendation does not grant marketing approval yet, the companies must submit Phase 4 study protocols within three months after receiving authorization. HIV infections in India rose from 57,549 in 2020 to 68,451 in 2023 before declining to 64,470 in 2024, according to recent data. Activists had urged the regulator to expedite approval and set a target price of $40 per person per year. The waiver could shorten the regulatory pathway that might otherwise have taken 18-24 months more, experts say.

## Indian Opinion Analysis

ThePrint leads with the regulatory waiver process, crediting the government panel's decision to expedite access. Times Now frames the same news through recent HIV infection data, implying urgency for prevention. This contrast in emphasis sets up a balanced reading: the waiver is real progress, but India's rising infections underscore why it matters. What remains to be monitored is CDSCO's final marketing authorization decision and the pricing the companies set, as the appeal cited a target of $40 per person per year.

## Coverage

Coverage: 2 sources, 2 neutral
- theprint.in (neutral report) <https://theprint.in/health/generic-lenacapavir-for-hiv-prevention-moves-closer-to-india-with-cdsco-waiver-of-local-phase-3-trials/3024080/>
  Leads with CDSCO waiver decision, framing it as a concrete step toward availability
- timesnownews.com (neutral report) <https://www.timesnownews.com/health/indias-silent-hiv-rise-the-twice-yearly-shot-that-could-transform-prevention-article-155987468>
  Leads with rising HIV infection data to frame the drug's importance, then reports the waiver

This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry.
Updated: this story now draws on 2 sources. Last updated 2026-08-26T10:26:53+00:00.

Tags: CDSCO, Dr Reddy's Laboratories, Emcure Pharmaceuticals, Gilead Sciences, HIV
Canonical: https://indianopinion.org/cdsco-panel-waives-phase-3-trials-for-generic-hiv-prevention-drug-lenacapavir/
License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources.
Cite: https://indianopinion.org/cdsco-panel-waives-phase-3-trials-for-generic-hiv-prevention-drug-lenacapavir/#story-in-brief

How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/